Adverse Effects of Drugs on Hemostasis and Thrombosis

Hau C. Kwaan; Charles L. Bennett

doi:10.1055/s-0032-1329596

Seminars in Thrombosis and Hemostasis, Table of Contents

Semin Thromb Hemost 2012; 38(08): 755-758
DOI: 10.1055/s-0032-1329596

Preface

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Adverse Effects of Drugs on Hemostasis and Thrombosis

Hau C. Kwaan

¹Division of Hematology and Oncology, Northwestern University Feinberg School of Medicine, Chicago, Illinois

,

Charles L. Bennett

²The Southern Network on Adverse Reactions (SONAR) Project, The South Carolina Center of Economic Excellence for Medication Safety, The South Carolina College of Pharmacy, Columbia, South Carolina

³Arnold School of Public Health of the University of South Carolina, Columbia, South Carolina

⁴WJB Dorn VA Medical Center, Columbia, South Carolina

⁵Hollings Cancer Center of the Medical University of South Carolina, Charleston, South Carolina

› Author Affiliations

Abstract

Full Text

References

References
1 Salmela B, Joutsi-Korhonen L, Armstrong E, Lassila R. Active online assessment of patients using new oral anticoagulants: bleeding risk, compliance, and coagulation analysis. Semin Thromb Hemost 2012; 38 (1) 23-30
2 Schulman S, Majeed A. The oral thrombin inhibitor dabigatran: strengths and weaknesses. Semin Thromb Hemost 2012; 38 (1) 7-15
3 Levi M. Safety of prohemostatic interventions. Semin Thromb Hemost 2012; 38 (3) 292-298
4 Maxwell WD, Bennett CL. Thromboprophylaxis guidelines in cancer with a primary focus on ambulatory patients receiving chemotherapy: a review from the Southern Network on Adverse Reactions (SONAR). Semin Thromb Hemost 2012; 38 (8) 759-767
5 Zangari M, Berno T, Zhan F, Tricot G, Fink L. Mechanisms of thrombosis in paraproteinemias: the effects of immunomodulatory drugs. Semin Thromb Hemost 2012; 38 (8) 768-779
6 Dy IA, Wiernik PH. Cocaine-levamisole thrombotic vasculopathy. Semin Thromb Hemost 2012; 38 (8) 780-782
7 Bennett CL, Spiegel DM, Macdougall IC , et al. A review of safety, efficacy, and utilization of erythropoietin, darbepoetin, and peginesatide for patients with cancer or chronic kidney disease: a report from the Southern Network on Adverse Reactions (SONAR). Semin Thromb Hemost 2012; 38 (8) 783-796
8 Artero A, Tarín JJ, Cano A. The adverse effects of estrogen and selective estrogen receptor modulators on hemostasis and thrombosis. Semin Thromb Hemost 2012; 38 (8) 797-807
9 McMahon BJ, Kwaan HC. Thrombotic and bleeding complications associated with chemotherapy. Semin Thromb Hemost 2012; 38 (8) 808-817
10 Loo AS, Gerzenshtein L, Ison MG. Antimicrobial drug-induced thrombocytopenia: a review of the literature. Semin Thromb Hemost 2012; 38 (8) 818-829
11 Auerbach E, Aboulafia DM. Venous and arterial thromboembolic complications associated with HIV infection and highly active antiretroviral therapy. Semin Thromb Hemost 2012; 38 (8) 830-838
12 Kreuter J, Winters JL. Drug-associated thrombotic microangiopathies. Semin Thromb Hemost 2012; 38 (8) 839-844
13 Jacob S, Dunn BL, Qureshi ZP , et al. Ticlopidine-, clopidogrel-, and prasugrel-associated thrombotic thrombocytopenic purpura: a 20-year review from the Southern Network in Adverse Reactions (SONAR). Semin Thromb Hemost 2012; 38 (8) 845-853
14 Baskurt OK, Meiselman HJ. Iatrogenic hyperviscosity and thrombosis. Semin Thromb Hemost 2012; 38 (8) 854-864
15 Scharf RE. Drugs that affect platelet function. Semin Thromb Hemost 2012; 38 (8) 865-883
16 Walenga JM, Thethi I, Lewis BE. Nonhemostatic adverse effects of anticoagulants and antiplatelet agents. Semin Thromb Hemost 2012; 38 (8) 884-892
17 Fung E, Patsopoulos N, Belknap SM , et al. The effect of genetic variants, especially CYP2C9 and VKORC1, on the pharmacology of warfarin. Semin Thromb Hemost 2012; 38 (8) 893-904
18 Moore TJ, Bennett CL. Underreporting of hemorrhagic and thrombotic complications of pharmaceuticals to the U.S. Food and Drug Administration: empirical findings for warfarin, clopidogrel, ticlopidine, and thalidomide. Semin Thromb Hemost 2012; 38 (8) 905-907